Sandrina Stacy Phipps

US Patent:

20030104624, Jun 5, 2003

Filed:

Feb 22, 2002

Appl. No.:

10/081961

Inventors:

Lori Clarke - Olney MD, US
Mario Gorziglia - Doleystown PA, US
Paul Hallenbeck - Gaithersburg MD, US
John Jakubczak - Germantown MD, US
Michael Kaleko - Rockville MD, US
Sandrina Phipps - Reston VA, US

International Classification:

C12N015/861
C12N015/74

US Classification:

435/456000, 435/320100, 435/325000

Abstract:

The present invention provides novel viral vectors and methods useful for the minimization of leaky gene expression, and, in particular, of nonspecific transcriptional read-through of genes. Such constructs may be obtained by the insertion of an insulating sequence into a vector construct, such as for example a termination signal sequence upstream of the transcription initiation site of the respective transcription unit.

US Patent:

20030104625, Jun 5, 2003

Filed:

Feb 22, 2002

Appl. No.:

10/081969

Inventors:

Cheng Cheng - Rockville MD, US
Lori Clarke - Olney MD, US
Sheila Connelly - Ijamsville MD, US
David Ennist - Bethesda MD, US
Mario Gorziglia - Doylestown PA, US
Paul Hallenbeck - Gaithersburg MD, US
Carl Hay - Damascus MD, US
John Jakubczak - Germantown MD, US
Michael Kaleko - Rockville MD, US
Sandrina Phipps - Reston VA, US
Seshidhar Police - Gaithersburg MD, US
Patricia Ryan - Montgomery Village MD, US
David Stewart - Eldersburg MD, US
Yuefeng Xie - Germantown MD, US

International Classification:

C12N015/861
C12N009/22
C12N007/00

US Classification:

435/456000, 435/199000, 435/235100, 435/320100

Abstract:

The present invention relates to oncolytic adenoviral vectors and their use in methods of gene therapy. Provided is a recombinant viral vector comprising an adenoviral nucleic acid backbone, wherein said nucleic acid backbone comprises in sequential order: A left ITR, a termination signal sequence, an E2F responsive promoter which is operably linked to a gene essential for replication of the recombinant viral vector, an adenoviral packaging signal, and a right ITR.

US Patent:

20070212675, Sep 13, 2007

Filed:

Apr 15, 2004

Appl. No.:

10/553459

Inventors:

Paul Hallenbeck - Chester Springs PA, US
Garret Hampton - San Diego CA, US
Carl Hay - Damascus MD, US
Ying Huang - Oleny MD, US
John Jakubczak - East Lyme CT, US
Sandrina Phipps - Reston VA, US

Assignee:

NOVARTIS AG - Basel
IRM LLC - Hamilton

International Classification:

C12Q 1/00

US Classification:

435004000

Abstract:

FEN1 transcriptional regulatory sequences (TREs) are provided. FEN1 TREs provide for transcriptional regulation dependent upon transcription factors that are only active in cancer cells. The FEN1 TREs may be used as a vehicle for introducing new genetic capability, particularly associated with cytotoxicity, for selective expression in cancer cells.